Day: July 12, 2015

BioPharma Dive: A 21st century diabetes option: Will Oramed be first to market with oral insulin?

Josh Hexter, Oramed’s COO, spoke with BioPharma Dive about Oramed’s product and progress. “Our oral insulin is not a substitute for insulin injections, but rather a new, earlier treatment option.” http://www.biopharmadive.com/news/a-21st-century-diabetes-option-will-oramed-be-first-to-market-with-oral-in/402100/

  • +1-844-9-ORAMED
  • office@oramed.com
  • 1185 Avenue of the Americas, New York, NY 10036 USA
Linkedin-in Facebook-f Twitter Youtube

Copyright © 2022 Oramed. | Terms & Conditions | Privacy Statement | Cookie Policy

Join our mailing list

  • +1-844-9-ORAMED
  • office@oramed.com
Linkedin-in Facebook-f Twitter Youtube
Home
About
Technology
Pipeline
Video Library
Contact us
NEWS
Press Releases
In the News
Scientific Articles and Abstracts
Events & Presentations
INVESTORS
Corporate presentation
Investor Relations
SEC filings
Investor FAQ
Governance documents
Investor tools
Oravax Medical
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset